UK medicines regulator says information on boxes of montelukast will alert users to risk of mood and behaviour changes
More than 500 adverse neuropsychiatric reactions have been reported in children under the age of nine involving an asthma drug which is to get new warnings over its risks.
The Medicines and Healthcare products Regulatory Agency (MHRA) announced last week that more prominent warnings would be added to the information provided on boxes of the asthma drug montelukast, sold under the brand name Singulair.
About Author
More Stories
Researchers create AI-based tool that restores age-damaged artworks in hours
23andMe’s founder wins bid to regain control of bankrupt DNA testing firm
European journalists targeted with Paragon Solutions spyware, say researchers